Regeneron's Pasatru Approved by FDA for Rare Bone Growth Disorder
The FDA has approved Regeneron's Pasatru for fibrodysplasia ossificans progressiva (FOP), a rare condition causing abnormal bone growth. The drug aims to slow disease progression, potentially preserving mobility and extending lifespan for patients who often rely on wheelchairs by age 25.
Regeneron Pharmaceuticals has secured FDA approval for Pasatru, a treatment for fibrodysplasia ossificans progressiva (FOP), a rare and debilitating condition where bone grows abnormally in muscles and connective tissues. The approval marks the culmination of a 30-year research effort to address this ultra-rare disease.
FOP typically leads to severe mobility loss, with most patients requiring wheelchairs by age 25 due to progressive bone accumulation that immobilizes limbs. Survival beyond the 50s is uncommon for those affected. The introduction of Pasatru offers hope for slowing disease progression, potentially preserving mobility and extending patients' lifespans.
## Clinical Trial Insights
Richard Keen, a primary investigator in Pasatru's pivotal trial and a specialist at London’s Royal National Orthopaedic Hospital, noted the drug's potential to alter the disease's trajectory. According to Keen, Pasatru nearly halts new bone formation, preventing further deterioration of the condition. This effect could significantly improve patients' quality of life by maintaining their physical function for longer.
## Treatment Impact and Future Outlook
While FOP remains a challenging condition, the approval of Pasatru represents a major milestone in its management. The drug's ability to inhibit abnormal bone growth provides a new therapeutic option for patients who previously had no effective treatments. Regeneron's achievement underscores the importance of sustained research in addressing rare diseases with limited treatment options.
